Press Release Details

Oct 21,2022

LEKLI Announces that the National Agency for Medicines and Medical Devices, has granted the Marketing Authorization for Lenalidomide (KAHLERMID L), an oral derivative of thalidomide, is an antineoplastic agent exhibiting antitumor activity through a variety of mechanisms, including immune system activation, angiogenesis inhibition and direct antineoplastic effects.

It has been extensively studied for the treatment of multiple myeloma and myelodysplastic syndrome as well as lymphoproliferative disorders including chronic lymphocyctic leukemia (CLL) and non-Hodgkin lymphoma.

TIRANË-- Oct 21, 2022—LEKLI sh.p.k. announced that the National Agency for Medicines and Medical Devices has validated the Marketing Authorization Application (MAA) for Lenalidomide (KAHLERMID L). The submission was supported by previously disclosed positive results of several years of work years of work to achieve this vital formula.

ABOUT LEKLI shpk

LEKLI shpk is a pharmaceutical company focused on market research and manufacture of medical products for human use.Our experience in pharmaceuticals began in 1986 and resulted in the establishment of LEKLI shpk in 1991 by Dr. Luan Lekli. During these years, LEKLI shpk managed to grow from a well- established Pharma company to a company with cross border presence.

In the following years, we specialized in the field of rare diseases, leading the market and making sure that every single patient is able to live a better life. In 2015, LEKLI shpk established a production facility, manufacturing generic drugs, Phytotherapeutics and orphan drugs. To cover all the needs of the Albanian market, we produce prescription, non-prescription, extemporaneous and stock pharmaceutical preparations.

Our experience spans more than 25 years in the Balkan market, during which we have established our presence through our operations in Albania and in Kosovo. Today we have a strong brand equity and awareness. Together with our highly motivated, experienced and empowered management team we lead the market in special indications areas.

LEKLI disclaims any obligation to update the information contained in this press release as new information becomes available.

LEKLI shpk :

Kristian Lekli, +355 69 720 3644

Besmira Basholli, +355 69 357 1311

David Lekli, +355 69 833 4620

Shpend Hasani, +383 44 197 654 (Kosove)

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.